论文部分内容阅读
[目的]观察顺铂(DDP)联合持续热灌注治疗胃癌腹腔转移腹水的疗效及不良反应。[方法]60例胃癌腹水患者分为顺铂联合腹腔持续热灌注组(治疗组)和单纯顺铂腹腔灌注化疗组(对照组),每组各30例。对两组生存期、控制腹水的近期疗效、不良反应进行观察。[结果]治疗组和对照组的中位生存期分别为10.2个月和5.9个月,有效率分别为76.7%和53.3%(P<0.05),治疗组不良反应无加重。[结论]DDP联合腹腔持续热灌注治疗胃癌腹水,能够提高疗效,延长生存期而不增加不良反应,值得进一步推广。
[Objective] To observe the efficacy and adverse reactions of cisplatin (DDP) combined with continuous thermal perfusion in the treatment of peritoneal ascites due to gastric cancer. [Method] Sixty patients with ascites from gastric cancer were divided into cisplatin plus intraperitoneal continuous thermal perfusion group (treatment group) and cisplatin alone intraperitoneal chemotherapy group (control group), 30 cases in each group. The two groups of survival, ascites control the short-term efficacy, adverse reactions were observed. [Results] The median survival time was 10.2 months in the treatment group and 5.9 months in the control group. The effective rates were 76.7% and 53.3% respectively (P <0.05), and the adverse reactions in the treatment group were not aggravated. [Conclusion] DDP combined with intraperitoneal continuous hot perfusion in the treatment of ascites of gastric cancer can improve the curative effect and extend the survival without increasing adverse reactions, which deserves further promotion.